USPTO serial 79211373
ANEMOCYTE
Reviewed by CopyMark Law Group
Reg. 5440621Status 739Registered
- Filing date
- Status date
- Registration date
- Apr 10, 2018
- Examiner
- EVANKO, PATRICIA MALESARDI
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with ANEMOCYTE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brian A. Tollefson
Brian A. Tollefson Tollefson IP326 First Street, #202Annapolis, MD 21403United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical [ and veterinary ] preparations, namely, [ recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues ] for use in human [ and veterinary ] medicine; chemical preparations for pharmaceutical or medical purposes, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues ] for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco skeletal, metabolic diseases, dermatology; prescription and non-prescription ] medicines, namely, [ pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, ] vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology [ , heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology ] ; biological preparations for the treatment of disorders in the field of cancer, immunology [ , heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology ] ; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes ] ; biological reagents for medical use; medicinal products based on cells and genes, namely, [ somatic cells, ] genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical [ and veterinary ] purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; [ biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, ] products for gene therapy, namely, [ genetically modified cells, viral vectors, ] nucleic acids; [ tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; ] [ products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; ] products for personalized medicine made of [ autologous cells or proteins or ] nucleid acids derived from individual genomic sequences; [ preparations made up of cells for medical or clinical use; ] preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes [ ; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy ] | ACTIVE | — |
| 042 | Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; medical information and data on research and development in the medical and veterinary fields; scientific and technological services, namely, scientific research and, literature scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology, consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ANEMOCYTE S.R.L.
- Other trademarks owned by ANEMOCYTE S.R.L.
- Other trademarks owned by ARETA INTERNATIONAL S.R.L.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ANEMOCYTE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 12, 2026 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Oct 14, 2026 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Oct 14, 2026 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Feb 9, 2026 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Feb 6, 2026 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Sep 16, 2025 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Sep 16, 2025 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Aug 22, 2025 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Aug 16, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jun 6, 2025 | PR75 | POST REGISTRATION ACTION MAILED - SEC. 71 & 15 | — |
| May 15, 2025 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| May 15, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 15, 2025 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| May 15, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 15, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 16, 2024 | PR75 | POST REGISTRATION ACTION MAILED - SEC. 71 & 15 | — |
| Nov 20, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 9, 2024 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Apr 10, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 24, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 24, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 24, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Oct 24, 2022 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Oct 24, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 24, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 24, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 9, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 11, 2018 | FINV | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 16, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 16, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 10, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 10, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 22, 2018 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Feb 10, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 23, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 23, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 3, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 3, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 3, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 11, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 11, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 11, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 11, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 20, 2017 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 20, 2017 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 4, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 18, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 18, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 12, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 12, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 11, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 8, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 8, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 7, 2017 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jul 6, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |